FDA Warns of Higher Risk for Death With Gout Drug Febuxostat FDA Warns of Higher Risk for Death With Gout Drug Febuxostat

Febuxostat should be reserved for patients with gout-related hyperuricemia for whom allopurinol has failed or who do not tolerate allopurinol, owing to an increased risk for death, the FDA says.News Alerts
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Rheumatology News Alert Source Type: news